{"id":"chop21","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"30-50%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CHOP21 is a combination of chemotherapy drugs, including cyclophosphamide, doxorubicin, vincristine, and prednisone, which work together to kill cancer cells. This regimen is typically used to treat non-Hodgkin lymphoma and other types of blood cancers.","oneSentence":"CHOP21 is a chemotherapy regimen used to treat various types of cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:47.093Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin lymphoma"},{"name":"Other types of blood cancers"}]},"trialDetails":[{"nctId":"NCT04884035","phase":"PHASE1","title":"Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","status":"RECRUITING","sponsor":"Celgene","startDate":"2021-09-15","conditions":"Lymphoma, B-Cell","enrollment":174},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":324},{"nctId":"NCT03731234","phase":"PHASE2","title":"Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2019-07-02","conditions":"DLBCL","enrollment":75},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT00278408","phase":"PHASE3","title":"Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2006-01-02","conditions":"Lymphoma","enrollment":700},{"nctId":"NCT06573645","phase":"PHASE3","title":"A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Xia Yi","startDate":"2024-08-23","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":428},{"nctId":"NCT03817853","phase":"PHASE4","title":"An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-02-26","conditions":"Advanced Follicular Lymphoma","enrollment":114},{"nctId":"NCT01393756","phase":"PHASE2","title":"Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2010-12","conditions":"Follicular Lymphoma","enrollment":80},{"nctId":"NCT02042391","phase":"PHASE2","title":"Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy","status":"COMPLETED","sponsor":"Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH","startDate":"2015-02-03","conditions":"Posttransplant Lymphoproliferative Disorder","enrollment":60},{"nctId":"NCT01332968","phase":"PHASE3","title":"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-06","conditions":"Non-Hodgkin's Lymphoma","enrollment":1401},{"nctId":"NCT02044276","phase":"PHASE3","title":"A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-03-31","conditions":"Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia","enrollment":101},{"nctId":"NCT03364439","phase":"PHASE2","title":"R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":109},{"nctId":"NCT01941680","phase":"","title":"High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant","status":"COMPLETED","sponsor":"University Hospital Center of Martinique","startDate":"2013-10-31","conditions":"T-cell Lymphoma, Leukaemia","enrollment":20},{"nctId":"NCT03283202","phase":"PHASE1","title":"Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-10-04","conditions":"Diffuse B-Cell Lymphoma","enrollment":35},{"nctId":"NCT00278421","phase":"PHASE3","title":"Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2005-11","conditions":"Lymphoma","enrollment":592},{"nctId":"NCT04544059","phase":"PHASE2","title":"Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2020-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":87},{"nctId":"NCT01285765","phase":"PHASE3","title":"Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2010-12","conditions":"DLBCL","enrollment":650},{"nctId":"NCT00064116","phase":"PHASE3","title":"Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2001-05-08","conditions":"Lymphoma","enrollment":824},{"nctId":"NCT01448096","phase":"PHASE2","title":"Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2011-08","conditions":"Large B Cell Diffuse Lymphoma","enrollment":33},{"nctId":"NCT00901615","phase":"PHASE1, PHASE2","title":"Lenalidomide and R-CHOP in B-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2009-01-06","conditions":"Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell Lymphoma","enrollment":108},{"nctId":"NCT02670317","phase":"PHASE2","title":"Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.","status":"TERMINATED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2016-09","conditions":"Lymphoma, B-Cell","enrollment":1},{"nctId":"NCT01539174","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fox Chase Cancer Center","startDate":"","conditions":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma","enrollment":""},{"nctId":"NCT01793844","phase":"","title":"A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2008-01","conditions":"Diffuse Large B-cell Lymphoma","enrollment":732},{"nctId":"NCT00144755","phase":"PHASE3","title":"R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2003-12","conditions":"Diffuse Large Cell Lymphoma","enrollment":600},{"nctId":"NCT00907348","phase":"PHASE2","title":"Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2007-10","conditions":"Non Hodgkin Lymphoma, Follicular Lymphoma","enrollment":49},{"nctId":"NCT00970385","phase":"PHASE3","title":"Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"1995-01","conditions":"Peripheral T Cell Lymphoma","enrollment":95},{"nctId":"NCT00850512","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy","status":"COMPLETED","sponsor":"University of Bologna","startDate":"","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":93,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CHOP 21 arm"],"phase":"phase_3","status":"active","brandName":"CHOP21","genericName":"CHOP21","companyName":"University Hospital, Grenoble","companyId":"university-hospital-grenoble","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHOP21 is a chemotherapy regimen used to treat various types of cancer. Used for Non-Hodgkin lymphoma, Other types of blood cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}